Plasma and urine cyclic nucleotide levels in patients with acute and chronic leukemia

M. Peracchi, L. Lombardi, A. T. Maiolo, F. Bamonti-Catena, V. Toschi, O. Chiorboli, R. Mozzana, E. E. Polli

Research output: Contribution to journalArticlepeer-review


Plasma and urine levels of cyclic adenosine 3',5'-monophosphate (cAMP) and of cyclic guanosine 3',5'-monophosphate (cGMP) were measured in 35 normal subjects, in 24 patients with nonneoplastic diseases (iron deficiency anemia, peptic ulcer, and cholelithiasis), and in 50 leukemic patients. The leukemic group included patients with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia. All patients were recently diagnosed and untreated, except for 5 patients with blastic transformation of chronic myelogenous leukemia who had been previously treated. There were no significant differences in plasma and urine cyclic nucleotide levels between normal subjects and patients with nonneoplastic diseases. In leukemic patients, plasma and urine cAMP levels were similar to those of normal subjects, whereas plasma and urine cGMP levels were markedly elevated. There were no significant differences in cGMP values between the various types of leukemia. After starting treatment, plasma cyclic nucleotide levels were periodically measured in 21 of the patients with acute leukemia; cGMP levels were normalized in all the 16 subjects who attained complete remission, whereas both cAMP and cGMP levels were apparently unaffected in the patients who did not respond to treatment. This suggests that plasma or urine cGMP could be used as an additional parameter to monitor the patient's response to treatment.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
Issue number3
Publication statusPublished - 1983

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Plasma and urine cyclic nucleotide levels in patients with acute and chronic leukemia'. Together they form a unique fingerprint.

Cite this